Savara Inc. Files 8-K: Material Agreement, FD Disclosure

TL;DR

Savara Inc. filed an 8-K on 10/29/25, reporting a material agreement and other key events.

AI Summary

On October 29, 2025, Savara Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and other events, along with financial statements and exhibits. The company, formerly known as Mast Therapeutics, Inc., is incorporated in Delaware and based in Austin, Texas.

Why It Matters

This 8-K filing indicates significant corporate activity, including a material definitive agreement and regulatory disclosures, which could impact investor understanding of the company's current status and future direction.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.

Key Numbers

• 001-32157 — SEC File Number (Identifies the company's filing with the SEC)
• 84-1318182 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Savara Inc. (company) — Registrant
• Mast Therapeutics, Inc. (company) — Former company name
• October 29, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Austin, Texas (location) — Business address city and state

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share SVRA The Nasdaq Global Se
• $75 million — Purchaser has agreed to pay the Company $75 million (the "Purchase Price") upon approval of
• $187.5 million — nd upon the receipt by the Purchaser of $187.5 million (the "Maximum Payment"). Based on the C

Filing Documents

• d55049d8k.htm (8-K) — 35KB
• d55049dex991.htm (EX-99.1) — 11KB
• d55049dex992.htm (EX-99.2) — 20KB
• g55049ex99_2s10g1.jpg (GRAPHIC) — 92KB
• g55049ex99_2s11g1.jpg (GRAPHIC) — 99KB
• g55049ex99_2s12g1.jpg (GRAPHIC) — 102KB
• g55049ex99_2s13g1.jpg (GRAPHIC) — 98KB
• g55049ex99_2s14g1.jpg (GRAPHIC) — 93KB
• g55049ex99_2s15g1.jpg (GRAPHIC) — 37KB
• g55049ex99_2s1g1.jpg (GRAPHIC) — 42KB
• g55049ex99_2s2g1.jpg (GRAPHIC) — 188KB
• g55049ex99_2s3g1.jpg (GRAPHIC) — 84KB
• g55049ex99_2s4g1.jpg (GRAPHIC) — 90KB
• g55049ex99_2s5g1.jpg (GRAPHIC) — 113KB
• g55049ex99_2s6g1.jpg (GRAPHIC) — 142KB
• g55049ex99_2s7g1.jpg (GRAPHIC) — 103KB
• g55049ex99_2s8g1.jpg (GRAPHIC) — 80KB
• g55049ex99_2s9g1.jpg (GRAPHIC) — 58KB
• g55049g1029081409400.jpg (GRAPHIC) — 3KB
• 0001193125-25-256290.txt ( ) — 2159KB
• svra-20251029.xsd (EX-101.SCH) — 3KB
• svra-20251029_lab.xml (EX-101.LAB) — 18KB
• svra-20251029_pre.xml (EX-101.PRE) — 11KB
• d55049d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements The Company cautions you that statements in this Current Report and the accompanying press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements related to the Company's expectations with respect to the description of the Purchase Agreement and the transactions contemplated thereby and statements regarding the pending litigation. The Company may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's ability to satisfy the conditions to closing in the Purchase Agreement; the risks associated with the Company's ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP; the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations; the availability of sufficient resources for the Company's operations and to conduct or continue planned clinical development programs; and the timing and ability of the Company to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detai

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Press Release of the Company issued on October 29, 2025. 99.2 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 29, 2025 SAVARA INC. a Delaware corporation By: /s/ Dave Lowrance Dave Lowrance Chief Financial & Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR